APST ALS-Netzwerktreffen: Status of research and care for ALS in Germany, 11.05.2023

On May 11, 2023, the APST ALS Network Meeting will take place in Berlin, followed directly by the MND-Net Meeting. The APST Network Meeting and the MND-Net Meeting serve to discuss current

Current status of genetics in ALS and Tofersen: ID-ALS study and hardship program.

We would like to briefly update you on the current status (03/01/2023) of the ID-ALS02 study and the transition to the Tofersen Hardship Program After the successful completion of the first part

Scientific publication on recording the course of the disease with the ALS app

The recording of the course of the disease amyotrophic lateral sclerosis (ALS) with the help of the ALS Functional Scale (ALSFRS-R) is of great relevance for those affected themselves, the ALS

The ALS app supports the first genetic therapy for ALS with mutation in the SOD1 gene.

Since March 2022, two patients have been treated with the drug Tofersen at the ALS outpatient clinic of the Charité in Berlin. The documentation and monitoring of the course of treatment are

Start of the Id-ALS study: identification of genetic alterations in people with ALS

The Id-ALS study is a research program to identify genetic alterations in people with amyotrophic lateral sclerosis (ALS). The study is organized by APST. The Alfried Krupp Hospital in Essen and